Ghrelin and obestatin: Different role in fetal lung development? by Nunes, S et al.
p e p t i d e s 2 9 ( 2 0 0 8 ) 2 1 5 0 – 2 1 5 8Ghrelin and obestatin: Different role in fetal lung
development?
Susana Nunes a,b, Cristina Nogueira-Silva a, Emanuel Dias a, Rute S. Moura a,
Jorge Correia-Pinto a,c,*
a Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal
bDepartment of Pediatrics, Hospital S. Marcos, Braga, Portugal
cDivision of Pediatric Surgery, Department of Pediatrics, Hospital S. Joa˜o, Porto, Portugal
a r t i c l e i n f o
Article history:
Received 4 January 2008
Received in revised form
7 August 2008
Accepted 8 August 2008
Published on line 26 August 2008
Keywords:
Ghrelin
Obestatin
GHS-R1a
GPR39
Fetal lung
Development
a b s t r a c t
Ghrelin and obestatin are two proteins that originate from post-translational processing of
the preproghrelin peptide. Various authors claim an opposed role of ghrelin and obestatin in
several systems. Preproghrelin mRNA is significantly expressed in airway epithelium
throughout lung development, predominantly during the earliest stages. The aim of this
study was to evaluate the role of ghrelin and obestatin in fetal lung development in vitro.
Immunohistochemistry studies were performed at different gestational ages in order to
clarify the expression pattern of ghrelin, GHS-R1a, obestatin and GPR39 during fetal lung
development. Fetal rat lung explants were harvested at 13.5 days post-conception (dpc) and
cultured during 4 days with increasing doses of total ghrelin, acylated ghrelin, desacyl-
ghrelin, ghrelin antagonist (D-Lys(3)-GHRP-6) or obestatin. Immunohistochemistry studies
demonstrated that ghrelin, GHS-R1a, obestatin and GPR39 proteins were expressed in
primitive rat lung epithelium throughout all studied gestational ages. Total and acylated
ghrelin supplementation significantly increased the total number of peripheral airway buds,
whereas desacyl-ghrelin induced no effect. Moreover, GHS-R1a antagonist significantly
decreased lung branching. Finally, obestatin supplementation induced no significant effect
in the measured parameters. The present study showed that ghrelin has a positive effect in
fetal lung development through its GHS-R1a receptor, whereas obestatin has no effect on
lung branching.
# 2008 Elsevier Inc. All rights reserved.
avai lable at www.sc iencedi rec t .com
journal homepage: www.e lsev ier .com/ locate /pept ides1. Introduction
Ghrelin is a 28-aminoacid acylated peptide mainly synthe-
sized in the endocrine A-like cells of the oxynticmucosa of the
stomach, that was originally described as a potent growth
hormone (GH) secretagogue interacting with the growth
hormone secretagogue receptor subtype 1a (GHS-R1a)
[23,26,30,34]. Moreover, ghrelin is a pleiotropic peptide with* Corresponding author at: Escola de Cieˆncias da Sau´de, Universidade
Tel.: +351 253 604 910; fax: +351 253 604 831.
E-mail address: jcp@ecsaude.uminho.pt (J. Correia-Pinto).
0196-9781/$ – see front matter # 2008 Elsevier Inc. All rights reserved
doi:10.1016/j.peptides.2008.08.012multiple roles described in various organs and systems as
recently reviewed by Leite-Moreira and Soares [25].
Throughout lung development, preproghrelin mRNA is
significantly expressed in airway epithelium, mainly during
the pseudoglandular stage, suggesting that ghrelin might act
as regulator of fetal lung development by autocrine/paracrine
mechanisms [37]. In this sequence, Santos et al demonstrated
that ghrelin expression was increased in hypoplastic lungsdo Minho, Campus de Gualtar, 4709-057 Braga, Portugal.
.
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hernia (CDH), whereas maternal treatment with ghrelin was
able to partially attenuate pulmonary hypoplasia in a CDH
experimental model [31]. On the other hand, in other adult
pulmonary diseases, ghrelin also seems to have beneficial
effects suggesting a role for ghrelin system in lung pathophy-
siology [5,18,32,38].
Ghrelin has the unique characteristic of having an
acylated group on one of its serine residues (Ser 3). This
acylation by n-octanoic acid is unstable but it is necessary for
the binding of ghrelin to the GHS-R1a. Therefore, acylated
ghrelin is often referred to as ‘‘active’’ ghrelin, although
desacyl-ghrelin represents >90% of total circulating ghrelin
in the adult rat. Even though the acylated form of ghrelin has
been recognized as the major active orexigenic molecule
regulating energy balance [7,19], recent data provides
evidence that differential influences of the acylated andFig. 1 – Ghrelin (a–d) and GHS-R1a (a0–d0) expression pattern durin
normal fetal lung, ghrelin and GHS-R1a expression was localize
and b0: 17.5 dpc; c and c0: 19.5 dpc; d and d0: 21.5 dpc). Scale bar
Fig. 2 – Obestatin (a–d) and GRP39 (a0–d0) expression pattern durin
normal fetal lung, obestatin and GPR39 expression was localize
and b0: 17.5 dpc; c and c0: 19.5 dpc; d and d0: 21.5 dpc). Scale barnon-acylated forms of the peptide must be considered [13].
Though the two ghrelin forms have a good chemical
correlation, they may have different actions [1,4,13,36].
Obestatin, is a newly discovered peptide encoded by the
preproghrelin and originated from post-translational proces-
sing of the preproghrelin peptide [41]. The effects of obestatin
aremediated through the deorphaned receptor GPR39, which
belongs to the family of class A rhodopsin receptors that also
include the ghrelin receptor (GHS-R1a) and motilin receptor
[26,41]. Although ghrelin and obestatin have the same origin,
several authors claim that their roles might be opposite. In
fact, obestatin appears to act as an anorexic hormone,
decreasing food intake, gastric emptying, jejunal motility
and body weight gain, antagonizing the actions of ghrelin
when both peptides are co-administered [41]. However, in
other systems obestatin is devoid of action, for instance it has
no effect on GH secretion [41]. Thus, the aim of this work wasg normal rat lung development. IHC studies showed that in
d to the primitive airway epithelium (a and a0: 15.5 dpc; b
, 15.5, 17.5 and 21.5 dpc = 100 mm; 19.5 dpc = 50 mm.
g normal rat lung development. IHC studies showed that in
d to the primitive airway epithelium (a and a0: 15.5 dpc; b
, 15.5 and 17.5 dpc = 100 mm; 19.5 and 21.5 dpc = 50 mm.
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concurrent effects during fetal lung development.2. Materials and methods
2.1. Animal model and experimental design
Animal experiments were performed according to the Portu-
guese law for animal welfare. Animals were housed in an
accredited mouse house and treated as specified in the ‘Guide
for theCare andUse of Laboratory Animals published by theUS
National Institutes of Health’s (National Institutes of Health
Publication No.85-23, revised 1996). Sprague–Dawley female
rats (225 g, Charles-River, Barcelona, Spain)weremaintained in
appropriate cages under controlled conditions, fed with
commercial solid food and after mating they were checked
for introital plugging. All pregnant rats were sacrificed by
decapitation. For immunohistochemistry studies, fetuses were
harvested by caesarean section at 15.5, 17.5, 19.5 and 21.5 dpc.
For lung explant cultures, fetuses were harvested at 13.5 dpc.
2.2. Immunohistochemistry studies (IHC)
Immunostainings were performed on formalin-fixed and
paraffin-embedded lung explants. Sections (5 mm)were placedFig. 3 – Branching morphogenesis in rat lung explant system tr
representative of lung explants at D0. Bottom panel represents
D4; B: total number of peripheral airway buds; C: epithelial perim
Numeric results are expressed as D4/D0 ratio. p < 0.05; *vs. conton SuperFrost1Plus slides (Menzel-Glaser, Braunschweig,
Germany). The ghrelin (1:50 dilution), obestatin (1:100 dilution)
and GPR39 antibodies (1:100 dilution) were obtained from
Phoenix Pharmaceuticals, Inc. (Burlingame, CA, USA). The
GHSR antibody (1:100) was obtained from Acris Antibodies
GmbH (Hiddenhausen, Germany).
After dewaxing in xylene and rehydration in ethanol,
antigen retrieval was achieved by boiling in 10 mM citrate
buffer followed by cool down at room temperature. The
sampleswere incubated in 3% hydrogen peroxide inmethanol
to quench endogenous peroxidase and blocked with 5% BSA
(Roche, Penzberg, Germany). Incubation of the primary anti-
body was performed at 4 8C overnight. Negative control
reactions included omission of the primary antibody. Incuba-
tion with the UltraVision detection system anti-polyvalent
horseradish peroxidase (Lab Vision Corporation, Fremont, CA,
USA) was carried according tomanufacturer’s instructions. To
visualize the peroxidase activitiy in sections, diaminobenzi-
dine tetrahydrochloride was used. The slides were counter-
stained with hematoxyline and photographed with Olympus
BX61 microscope (Olympus, Tokyo, Japan).
2.3. Fetal lung explant cultures
Fetuses were removed by caesarean section at 13.5 dpc.
Harvesting and dissection of the lungs was made in DPBSeated with different total ghrelin doses. A: upper panel is
lung explants treated with different total ghrelin doses, at
eter. Scale bar, 6349 mm (all images at samemagnification).
rol (0 nM).
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(Leica MZFLIII, Wetzlar, Germany). The lungs were trans-
ferred to Nucleopore membranes with an 8 mm pore size
(Whatman, Clifton, NJ, USA) and incubated in a 24-well
culture plates from Costar (Corning, NY, USA). Membranes
were presoaked in DMEM (Lonza) for 1 h before the explants
were placed on them. Floating cultures of the explants were
incubated in 200 mL of 50% DMEM, 50% nutrient mixture F-12
(Invitrogen, Carlsbad, CA, USA) supplemented with 100 mg/
mL streptomycin, 100 units/mL penicillin (Invitrogen),
0.25 mg/mL ascorbic acid (Sigma–Aldrich, St Louis, MO,
USA) and10% fetal calf serum(Invitrogen). Fetal lungexplants
were incubated in a 5%CO2 incubator at 37 8C for 96 h, and the
medium was replaced every 48 h. Increasing doses of total
ghrelin (0 nM, n = 10; 0.03 nM, n = 10; 0.3 nM, n = 10; 3 nM,
n = 10; 30 nM, n = 12), acylated ghrelin (0 nM, n = 10; 0.03 nM,
n = 12; 0.3 nM, n = 10; 3 nM, n = 10; 30 nM, n = 10), desacyl-
ghrelin (0 nM, n = 10; 0.03 nM, n = 10; 0.3 nM, n = 10; 3 nM,
n = 10; 30 nM, n = 10), ghrelin antagonist—D-Lys(3)-GHRP-6
(0 nM, n = 10; 10 nM, n = 10; 100 nM, n = 10; 1000 nM, n = 10) or
obestatin (0 nM, n = 8; 0.5 nM, n = 8; 5 nM, n = 8; 50 nM, n = 8;
100 nM,n = 8; 500 nM, n = 9)were addeddaily. The total (rat, 1–
28), acylated (rat, 1–5), and desacyl-ghrelin as well as ghrelin
antagonist were obtained from the Peptides International
(Louisville, KY, USA). Obestatin was obtained from Anaspec,
Inc. (San Jose, CA, USA).Fig. 4 – Branching morphogenesis in rat lung explant system tre
representative of lung explants at D0. Bottom panel represents l
at D4; B: total number of peripheral airway buds; C: epithelial p
magnification). Numeric results are expressed as D4/D0 ratio. p2.4. Morphometric analysis
The branching morphogenesis was monitored daily by photo-
graphing the explants. At day 0 (D0: 0 h) and 4 (D4: 96 h) of
culture, the total number of peripheral airway buds (branching)
in all lung explants was determined, whereas the epithelial
perimeter and total explant area were measured using
AxionVision Rel. 4.3 (Carl Zeiss, Gottingen, Germany). For all
experimental conditions, theresultsofbranchingandepithelial
perimeter were expressed as D4/D0 ratio.
2.5. Statistical analysis
All quantitative data are presented as mean  SEM. For
statistical analysis one-way ANOVA was performed, using
SigmaStat 3.5 (Systat, San Jose, CA, USA). The Student–
Newman-Keuls test was used for post-test analysis. Statistical
significance was set at p < 0.05.3. Results
3.1. IHC studies
IHC studies revealed that ghrelin and GHS-R1a were pre-
dominantly expressed in primitive lung epithelium during allated with different acylated ghrelin doses. A: upper panel is
ung explants treated with different acylated ghrelin doses,
erimeter. Scale bar, 6349 mm (all images at same
< 0.05; * vs. control (0 nM), § vs. 0.03 nM.
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that obestatin and GPR39 were expressed in primitive lung
epithelium throughout all studied gestational ages (Fig. 2).
3.2. Total, acylated and desacyl-ghrelin supplementation
studies
For the current protocol 243 lung explants were cultured. In
order to evaluate ghrelin role during lungmorphogenesis, fetal
lung explants were treated with different doses of recombi-
nant total, acylated and desacyl ghrelin.
In Fig. 3A, representative examples of fetal lung explants
treated with increasing doses of total ghrelin are illustrated.
Total ghrelin appears to have an enhancing effect on lung
explants growth in all the studied doses. The results of
morphometric analysis on fetal lung explants are summarized
in Fig. 3B and C. Increasing doses of total ghrelin induced a
progressive and positive effect on total number of peripheral
airway buds (Fig. 3B), although this effect was not evident on
epithelial perimeter (Fig. 3C).
In Fig. 4A, representative examples of fetal lung explants
treated with increasing acylated ghrelin doses are illustrated.
Acylated ghrelin appears to have an enhancing effect on lung
explants growth in a dose dependent way. The results of
morphometric analysis of fetal lung explants are summarized
in Fig. 4B and C. Increasing acylated ghrelin doses induced aFig. 5 – Branching morphogenesis in rat lung explant system tre
representative of lung explants at D0. Bottom panel represents
at D4; B: total number of peripheral airway buds; C: epithelial p
magnification). Numeric results are expressed as D4/D0 ratio.positive effect on total number of peripheral airway buds as
well as on epithelial perimeter. Treatment with 30 nM of
acylated ghrelin induced a maximal and statistically signifi-
cant growth regarding the number of peripheral airway buds
(Fig. 4B). Treatment with 3 and 30 nM of acylated ghrelin
induced a maximal and statistically significant growth
regarding the epithelial perimeter (Fig. 4C).
In Fig. 5A, representative examples of fetal lung explants
treated with increasing desacyl-ghrelin doses are illustrated.
Desacyl-ghrelin appears to have no effects on lung explants
growth at all the studied doses. The results of morphometric
analysis on fetal lung explants are summarized in Fig. 5B and
C. No significant differences were observed in lungs, neither
on the total number of peripheral airway nor on epithelial
perimeter.
3.3. GHS-R1a antagonist supplementation studies
In order to clarify the involvement of GHR-S in the response to
ghrelin, lung explants were treated with D-Lys(3)-GHRP-6 on
the lung development was examined. The D-Lys(3)-GHRP-6 is
a specific receptor antagonist of GHS-R1a that is able to
interact with the GHS-R1a inhibiting the interaction of ghrelin
with this receptor. In Fig. 6A, representative examples of fetal
lung explants treated with increasing GHS-R1a antagonist
doses are illustrated. GHS-R1a antagonist seems to have anated with different desacyl-ghrelin doses. A: upper panel is
lung explants treated with different desacyl-ghrelin doses,
erimeter. Scale bar, 6349 mm (all images at same
Fig. 6 – Branching morphogenesis in rat lung explant system treated with different GHS-R1a antagonist doses. A: upper
panel is representative of lung explants at D0. Bottom panel represents lung explants treated with different GHS-R1a
antagonist doses, at D4; B: total number of peripheral airway buds; C: epithelial perimeter. Scale bar, 6349 mm (all images at
same magnification). Numeric results are expressed as D4/D0 ratio. p < 0.05; *vs. control (0 nM).
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doses. The results of morphometric analysis on fetal lung
explants are summarized in Fig. 6B and C and confirm this
inhibitory effect on total number of peripheral airway buds
and epithelial perimeter.
3.4. Obestatin supplementation studies
In order to evaluate obestatin role during lungmorphogenesis,
fetal lung explants were treated with different doses of
recombinant rat obestatin. In Fig. 7A, representative examples
of fetal lung explants treated with increasing obestatin doses
are illustrated. Obestatin appears to have no effects on lung
explants growth at all the studied doses. The results of
morphometric analysis on fetal lung explants are summarized
in Fig. 7B and C and corroborate the lack of effects.4. Discussion
This study confirms that ghrelin has a developmental effect
during fetal lung growth likely through GHS-R1a receptor. In
contrast, although obestatin is expressed in the fetal lung, it
does not seem to have a physiological relevant role.
These results demonstrate that ghrelin, obestatin and their
respective receptors (GHS-R1a and GPR39) are expressed inlung epithelium throughout all studied gestational ages,
suggesting their involvement in lung development mechan-
isms. Ghrelin was first identified in the neuroendocrine cell
compartment of the oxyntic mucosa of the stomach [7,23].
Subsequently, it was also demonstrated that ghrelin is
expressed in the pituitary gland, arcuate nucleus of the
hypothalamus, duodenum, jejunum, ileum, colon, testis and
also in branching organs such as kidney, pancreas, mammary
gland and placenta [7,12,16,23,27]. Volante et al. [37] had
already demonstrated that ghrelin is expressed in neuroendo-
crine cells of the bronchial wall during lung development.
Moreover, Santos et al. [31] documented by in situ hybridiza-
tion and immunohistochemistry that ghrelin is expressed in
fetal lung epithelium. So, these studies corroborate the
present results. Relatively to GHS-R1a expression pattern, it
has already been described that this ghrelin receptor is widely
expressed in different systems such as the hypothalamic-
pituitary, cardiovascular, immune, gastrointestinal, and
reproductive, reflecting the pleiotropic activity of its ligand
[40]. In the present study, it is documented that GHS-R1a is
expressed in fetal lung. Previously, Santos et al. [31] performed
PCR studies in human and rat lungs, but GHS-R1a could not be
amplified. This apparent contradiction might be explained by
the use of different experimental techniques (immunohisto-
chemistry to study protein expression and PCR to studymRNA
expression).
Fig. 7 – Branching morphogenesis in rat lung explant system treated with different obestatin doses. A: upper panel is
representative of lung explants at D0. Bottom panel represents lung explants treated with different obestatin doses, at D4; B:
total number of peripheral airway buds; C: epithelial perimeter. Scale bar, 6349 mm (all images at same magnification).
Numeric results are expressed as D4/D0 ratio.
p e p t i d e s 2 9 ( 2 0 0 8 ) 2 1 5 0 – 2 1 5 82156Regarding obestatin expression, it was previously
described that obestatin is expressed in gastric mucosa,
myenteric ganglion cells, Leydig cells of the testis and
pancreatic islets [9,42]. The present work demonstrates that
obestatin is also expressed in lung epithelium. Moreover, it is
provided the first immunohistochemical evidence of the
GPR39 expression in fetal epithelial lung cells. GPR39 expres-
sion was only previously demonstrated by RT-PCR analysis, in
the gastrointestinal tract, liver, pancreas, kidney, adipose
tissue and central nervous system.
In order to clarify whether ghrelin and obestatin play some
role on lung morphogenesis, supplementation studies were
performed,usinga fetal lungexplantsculturesystem.Bothtotal
and acylated ghrelin induced a positive effect on fetal lung
branching, confirming in vitro the results described in vivo by
Santos et al. [31]. On the other hand, supplementation with
desacyl-ghrelin showed no effect and ghrelin antagonist
supplementation induced an inhibitory effect on lung growth.
Theseresults clearly suggest that fetal lungeffectsofghrelinare
mainly mediated through a GHS-R1a pathway. These findings
are in agreement with previous studies in other organs. In this
work, D-Lys(3)-GHRP-6 was the ghrelin antagonist used. This
ghrelinantagonisthas beenbeingused inmanyother studies in
order to characterize the subtype of receptor involved in the
variousactionsof ghrelin [3,6,8,10,11,17,21,22,28,29,33,43].After
obestatin description, several authors suggested that it might
haveanoppositeeffect toghrelin.For instance, obestatinhasananorexigenic effect and has a sleep-promoting effect [34,35,43].
In this work it was demonstrated the expression of obestatin
andGPR39infetal lung,howeverthesepeptidesdidnothaveany
effect in lung growth. This observation is in agreementwith the
literature that describes that obestatin do not have a physio-
logical role and that ghrelin and obestatin do not necessarily
present opposed effects. The initial claim of obestatin role on
inhibition of food intake, body weight gain, satiety signalling,
gastric emptying and intestinalmotility in rodents, through the
activation of the GPR39 receptor, has not been easily replicated
[2,14,15]. Moreover, Yamamoto et al. showed that the intracer-
ebroventricular injectionofobestatindidnothaveastimulating
effect of the pituitary hormones secretions (plasma GH, PRL,
ACTH and TSH levels) despite the presence of GPR39 in the
pituitary [39]. Furthermore, it was demonstrated that ghrelin is
synthesized by cardiomyocytes and has a direct effect on its
viability, however Iglesias et al. did not find any relevant
metabolic or viability effects ofobestatin [20]. In thesame trend,
Lagoetal.claimthat,unlikeghrelin,obestatindoesnotexertany
relevant activity in chondrocytes [24].5. Conclusion
The present study showed that ghrelin has a positive effect in
fetal lung development through its GHS-R1a receptor, whereas
obestatin has no effect on lung branching.
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